| Description | Tilomisole (Wy 18251) is an orally available benzimidazole thiazole with anti-inflammatory activity and immunomodulatory activity.Tilomisole is used in the study of cancer and inflammation. |
| In vitro | Tilomisole (100 μg/ml) 通过恢复 RA T 细胞的缺陷因子生产而恢复正常。Indomethacin (1 microgram/ml) 能够产生相似的效果，但 levamisole (0.1-100 μg/ml) 则不能，这表明 Tilomisole 在该系统中的作用是由于其抑制前列腺素生物合成的能力。尽管如此，Tilomisole 调节下降 B 细胞功能的能力可能也对该化合物的抗关节炎活性有所贡献。[3] |
| Synonyms | Wy 18251 |
| molecular weight | 342.8 |
| Molecular formula | C17H11ClN2O2S |
| CAS | 58433-11-7 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (145.86 mM) |
| References | 1. Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4(1):10-14. 2. Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies. Bioorg Chem. 2022;120:105644. 3. Gilman SC, et al. Effects of tilomisole, indomethacin and levamisole on regulation of Epstein Barr virus-induced B cell proliferation by peripheral blood mononuclear cells from normal individuals and patients with rheumatoid arthritis. Agents Actions. 1987;21(3-4):266-268. |